Gemcitabine

A phase 3 study of acelarin in combination with cisplatin for biliary tract cancer is being discontinued at the recommendation of the study’s independent data monitoring committee, according to a press release from the agent’s manufacturer.

The addition of berzosertib to gemcitabine extended PFS for women with platinum-resistant, high-grade serous ovarian cancer, according to results of a randomized phase 2 study published in The Lancet Oncology.